Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. - Wikidata - wikimedia - TriplyDB

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

http://www.wikidata.org/entity/Q34300803

about

BRCAness: finding the Achilles heel in ovarian cancer Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine Connectivity Homology Enables Inter-Species Network Models of Synthetic Lethality Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.Pre-exposure to ionizing radiation stimulates DNA double strand break end resection, promoting the use of homologous recombination repair Approaches to identifying synthetic lethal interactions in cancer.Surgical delivery of drug releasing poly(lactic-co-glycolic acid)/poly(ethylene glycol) paste with in vivo effects against glioblastoma.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer.Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.Mechanisms and consequences of ATMIN repression in hypoxic conditions: roles for p53 and HIF-1.Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway.Harnessing synthetic lethal interactions in anticancer drug discovery Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.New paradigms and future challenges in radiation oncology: an update of biological targets and technology.Therapeutic potential of PARP inhibitors for metastatic breast cancer.Carbogen gas and radiotherapy outcomes in prostate cancer.Tumor hypoxia as a driving force in genetic instability.An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment Synthetic lethality and cancer.Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.ATM activation in hypoxia - causes and consequences.Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.Metformin is synthetically lethal with glucose withdrawal in cancer cells.Targeting radiation-resistant hypoxic tumour cells through ATR inhibition Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells.

P2860

Q24630872-DA8DF556-2AAF-4F08-A625-E711FF4CBD4A Q26766638-8A2B8465-849B-4AEB-AF17-28217B9F4F13 Q26768267-60525DF5-A5F8-4512-B02D-B25950934818 Q26768661-7338AE34-9194-482C-9ACF-1693287ABF00 Q28071345-F278BDE1-D526-481D-9C71-7CB9D00B5B6F Q28072204-A8510A82-67A4-43D8-9735-6453B9B49F14 Q28550178-F390CE45-1B8C-4FFA-AB2A-F7A483793DF6 Q33584594-EEB6CE3B-0578-41AC-A874-6CD0D9050E88 Q33621410-578924A6-931F-45B7-9E93-AFC70924D84A Q33649555-DC47E53D-FEC9-41F3-A355-E44F483DF282 Q34458291-0147B542-D838-4D8F-9225-254E094379ED Q35119267-7A383577-D9A1-43C5-A3F1-182332A4D9B1 Q35235233-26B4685C-B308-4559-B32C-9DB6FC9D0AF0 Q35647469-D36C2751-A1C0-4E15-BDA3-B191A2256567 Q35758314-CB307BC0-157F-46B5-9014-C3034990A52F Q35837949-EAECB0EE-7207-4CCC-AFE1-E942D0433D21 Q36144711-8E316060-39FE-4357-B60D-F4B336876B19 Q36211573-14611753-BDD0-4B21-BC19-AA06029DC52A Q36544857-92663E2A-E378-4795-9A9D-3C9CA14A387A Q36580272-7F926978-F87E-413A-AB05-2B9B6A060790 Q36623493-6348D178-07BD-44BC-8BC8-1DA4EFB70734 Q36675088-6A517CFA-5B57-4FDB-9EE1-3631A7002B00 Q36839571-325F29E7-8E73-4858-8637-A193FE9A15AA Q36869865-F6C1CBA5-6BB8-463E-81D4-01211F54E675 Q36941966-40B88E90-744D-418D-B250-91729129C0D5 Q37122690-6FA2A388-C772-4734-861A-0E7834715527 Q37160539-48206225-0140-4A30-BE00-AC58333320D6 Q37931893-349979A5-59BD-4F57-819B-75CDC945D237 Q38078362-6F7347C4-266C-4587-9405-329D63E1C418 Q38155002-374FFAAF-23CE-46A4-9990-0931BA61E4DB Q38192714-F34CEAEF-A0BD-4E30-BB3B-5B8F1D1562E2 Q38468410-4ACE0846-B1CE-4549-81D3-0CE202B59075 Q38709651-EBEF4B1D-9AB4-4880-8BCA-4C3C70CD365B Q38806173-56D32611-105B-436E-B0F5-073480BCC928 Q38864240-909A559F-DD92-4B68-BAC3-7E14F3F083C7 Q38866639-403699DE-72B8-4179-81E6-D0DA713C8098 Q38918312-665F3373-7481-450E-ADE1-46708BCD9967 Q39312255-7FF9C993-57E8-4339-AD77-15898E300D07 Q39328356-22DB1F24-8F96-4A33-B329-A3C841BC667A Q39364897-770987EC-86D8-40C2-A131-A16AE40A1701

P2860

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

http://www.wikidata.org/entity/Q34300803

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@ast

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@en

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@nl

type

label

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@ast

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@en

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@nl

prefLabel

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@ast

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@en

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

@nl

P1433

Q34300803-F55CDFB9-EAE1-4E0F-A5C9-E989A1D5087A

P1476

Q34300803-9B3E3333-0EDA-4C8C-961F-894B4D3AFE44

P2093

Q34300803-01134A72-AE76-48D3-934F-9CD10DAE8A46

Q34300803-19D3D4DE-C5B0-450D-81D3-A58A5DDE7BA9

Q34300803-21959F38-90D6-4193-BE4B-7E2F47DF206B

Q34300803-23A605DF-69CB-4DDA-905D-9136766B7667

Q34300803-334A924D-648A-45AC-8E15-B66AFF0B708A

Q34300803-6B116CCD-86FA-4351-8AA2-684167BA8050

Q34300803-9E9A8383-69AD-4AC9-9E76-4D1BA9515073

Q34300803-A5EA0CDB-8465-43DD-A01F-564B1100A83B

Q34300803-DAFAD478-41F7-4F39-80FA-79C384562107

P2860

Q34300803-08580FC9-3FF0-4E00-9A1C-8339E2692DE1

Q34300803-0A4C266B-D03A-4C9D-A229-987155C6368B

Q34300803-0D42D2FF-A589-4E9E-8D4B-E210794C0A01

Q34300803-0E0E8DF4-21E6-4AEF-B506-830532CA5367

Q34300803-0FA1A94D-5C49-4A7F-B622-7B8A6C2C77A1

Q34300803-1045F0D7-89A1-49FC-A9EC-ADFA52585EC3

Q34300803-243591A1-B2B2-47D2-A16E-B400B544980C

Q34300803-2B6AE132-3325-4EF3-A59B-46DC022B57AF

Q34300803-2D06838D-A698-4BFC-BD4B-0F92ACBD90EA

Q34300803-2E53F77E-46BD-402C-A348-3B40FA0BAD0A

P304

Q34300803-793B223A-406B-4EB1-B3A4-FA55BAA79F78

P31

Q34300803-6C6A8F22-F15A-481E-AD29-FDDE035C15A8

P356

Q34300803-EA8B5292-5D07-4508-BE2D-1306F0761CAA

P407

Q34300803-FA46EDFE-777F-4B3A-9EA5-C57D987DC791

P433

Q34300803-D5D552DA-0CF9-4217-9F9F-D1C2D96F62BE

P478

Q34300803-4980F3CA-7BDB-4CA1-A5FB-06330C8484D9

P50

Q34300803-49D65899-512C-4997-AF88-2FA169835831

Q34300803-4CDA1925-7FAD-4AFA-A8E2-3B201C219CCC

Q34300803-A21F4C8C-5066-449D-86D5-56DE6E62B7C8

P577

Q34300803-53124249-354B-4485-8A93-5562FD0F56BD

P698

Q34300803-B41E67E8-246B-4D33-928D-EF4F939001CB

P932

Q34300803-88E164A0-BD16-4ADB-BD62-F24135885382

P356

0008-5472.CAN-10-2352

P1433

Cancer Research

P1476

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment

@en

P2093

Carla Coackley

http://www.w3.org/2001/XMLSchema#string

Ester M Hammond

http://www.w3.org/2001/XMLSchema#string

F Javier Oliver

http://www.w3.org/2001/XMLSchema#string

Kaisa R Luoto

http://www.w3.org/2001/XMLSchema#string

Minalini Lakshman

http://www.w3.org/2001/XMLSchema#string

Nirmal Bhogal

http://www.w3.org/2001/XMLSchema#string

Norman Chan

http://www.w3.org/2001/XMLSchema#string

Ponnari Gottipati

http://www.w3.org/2001/XMLSchema#string

Zuzana Bencokova

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis

Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy

Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer

Exploiting tumour hypoxia in cancer treatment

Resistance to therapy caused by intragenic deletion in BRCA2

Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

P304

8045-8054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-2352

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Helleday

Robert G. Bristow

P577

2010-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20924112

http://www.w3.org/2001/XMLSchema#string

P932

2978949

http://www.w3.org/2001/XMLSchema#string